Reversible Spheroid Cancer Cell Model for Metastatic Phenotype Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models for cancer drug screening often fail to effectively identify anti-cancer agents due to their inability to accurately represent the aggressive and chemoresistant metastatic phenotype, as they either circumvent key features of metastasis or are confounded by the three-dimensional architecture of spheroids, leading to misleading results on drug efficacy.
Innovation Solution
A modified two-step cell culture procedure involving the isolation and reversal of anchorage-independent spheroids into monolayer cells, without the use of chemical agents, to create a more accurate in vitro model that mimics the metastatic phenotype, allowing for targeted drug screening against cancer stem-like cells and overcoming chemoresistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If in vivo methods are used to characterize tumorigenic potential, then the tumorigenic potential of cancer cells can be characterized, but the key features of metastatic cascade such as invasion, migration, and epithelial-mesenchymal transition are circumvented or evaded
Solution Approach 1:
The patent segments the metastatic cascade into distinct phases and uses separate in vitro assays for each phase: Boyden chamber for invasion, transwell for migration, and spheroid formation for EMT. This segmentation allows each feature to be measured independently without the confounding factors present in whole-animal models.
Solution Approach 2:
The patent transitions from two-dimensional monolayer cultures to three-dimensional spheroid cultures to better recapitulate the in vivo tumor microenvironment. This dimensional change enables the study of EMT and other three-dimensional metastatic processes that cannot be observed in traditional 2D models.
2Measurement precision
If Boyden chamber design is used to demonstrate invasion of cancer cells, then local-invasion can be demonstrated, but EMT and cancer-stemness/tumorigenic potential are not captured
Solution Approach 1:
The patent merges multiple complementary in vitro assays into an integrated metastatic cascade model. The Boyden chamber assay for invasion is combined with spheroid formation assays for EMT and tumorigenicity assessment, creating a comprehensive model that captures all key features of metastasis simultaneously.
3Reliability
If three dimensional culture is used to mimic in vivo tumor, then cancer stem cell markers and potential for metastasis are possessed, but the manifestation of metastatic phenotype remains unclear and drug sensitivity may be misleading
Solution Approach 1:
The patent performs preliminary characterization of spheroid-forming cells to identify and enrich for the metastatic phenotype before conducting drug screening. This preliminary action ensures that the cells being tested have the relevant metastatic characteristics, making subsequent drug efficacy assessments more reliable and clinically relevant.
4Ease of operation
If conventional two dimensional culture is used for drug screening, then the assay is simple to perform, but it cannot distinguish between innate chemoresistance and physical barriers to drug penetration
Solution Approach 1:
The patent employs three-dimensional spheroid cultures instead of traditional two-dimensional monolayers. This dimensional change creates a physical barrier that mimics the tumor microenvironment, allowing researchers to distinguish between drugs that can penetrate physical barriers and those that are inherently ineffective against metastatic cells.
Data Source
AI summary
The present invention relates to drug discovery and development. More specifically, the present invention provides methods and composition useful for screening anti-cancer agents. In a specific embodiment, a method for screening candidate anti-cancer agents comprises the steps of (a) contacting a monolayer of reversible spheroid cancer cells with a candidate anti-cancer agent; and (b) measuring the response of the reversible spheroid cancer cells to the candidate anti-cancer agent.